Overview

NGR-hTNF Administered in Combination With a Standard Oxaliplatin Based Regimen in Patients With Metastatic Colorectal Cancer

Status:
Completed

Trial end date:
2013-05-01

Target enrollment:

Participant gender:

Summary

The main objective of the trial is to document the safety of NGR-hTNF administered at low and high doses in combination with a standard oxaliplatin based regimen in patients with metastatic colorectal cancer not amenable to any clinical improvement by current standard treatments

Phase:

Phase 2

Details

Lead Sponsor:

AGC Biologics S.p.A.
MolMed S.p.A.

Treatments:

Capecitabine
Oxaliplatin